Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements The accompanying notes are an integral part of these interim condensed consolidated financial statements. | --- | --- | --- | --- | |-------------------------------------------|-------|-----------------------|-------------------------------| | (in thousands of EUR) Assets | Note | December 31, 2022 | June 30, 2023 \n(unaudited) | | Non-current assets | | | | | Intangible assets and goodwill | 6.1 | 31,778 | 31,700 | | Pr ...

Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements CureVac N.V. | --- | --- | --- | --- | |---------------------------------------------------------------|-------|---------------------------------------|----------------------------| | (in thousands of EUR, except per share amounts) | Note | Three months \n2022 (unaudited) | ended March 31, \n2023 | | Revenue | 3.1 | 24,373 | 7,129 | | Cost of sales | 3.2 | (37,232) | (20,634) | | Selling and distribution expenses | 3.3 | (271) | (824 ...

CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Conference Call April 25, 2023 9:00 AM ET Company Participants Alexander Zehnder - CEO Pierre Kemula - CFO Myriam Mendila - Chief Development Officer Sarah Fakih - VP Corporate Communications and IR Conference Call Participants Jonathan Miller - Evercore ISI Ellie Merle - UBS Eun Yang - Jefferies Roy Buchanan - JMP Securities Evan Wang - Guggenheim Partners Andy Chen - Berenberg Luisa Morgado - Kempen Charlie Yang - Bank of America Operator Greetings, and welcome ...

$Capital raise of $250 million in Feb 2023 Validated mRNA Platform Corporate Development Growing the talent base: >1,100 employees New sites State-of-the-art technologies Financial Execution CureVac Pipeline: A Diversified Portfolio Manufacturing ▪ The RNA Printer: Obtain first manufacturing licenses for drug substance oncology constructs H2 CureVac │ Fourth Quarter and Full-Year 2022 Results | 8 Flu SV mRNA: modified monovalent ▪ Licensed comparator vaccine CV0501: modified monovalent ▪ Fully enrolled with ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001 ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update · In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint o Monovalent modified COVID-19 candidate CV0501 demonstrated efficient booster activity and good tolerability across now available dose range of 3 to 200µg o Modified mRNA technology selected as preferred technology; on track with new clin ...

Third Quarter and First Nine Months 2022 Financial Results and Business Update November 16, 2022 CureVac Speakers Interim Chief Development Officer | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------|------------------|-------|-------|-------|-------|-------|-------| | Franz-Werner Haas \nChief Executive Officer | Business Update | | | | | | | | Ulrike Gnad-Vogt | Program Update | | | | | | | | | | | | | | | | | Ronald Plasterk | Program Update | | | | | | | | SV ...

Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk - SVP Science & Innovation Sarah Fakih - VP Corporate Communications and IR Conference Call Participants Geoff Meacham - Bank of America Evan Wang - Guggenheim Jonathan Miller - Evercore Roy Buchanan - JMP Securities Zhiqiang Shu - Berenberg ...

Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of September 30, 2022 and December 31, 2021 and for the nine months ended September 30, 2022 and 2021 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) | --- | --- | --- | --- | |-------------------------------------------------------------------------|-------|------------------------------|------------------------| | | Note | Nine months ended \n2021 | Septembe ...

CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) | --- | --- | --- | --- | |---------------------------------------------------------------|-------|-------------------------------------|---------------------------| | (in thousands of EUR, except per share amounts) | Note | Six months \n2021 (unaudited) | e ...